Literature DB >> 29098139

In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies.

M C Sharma1, S Jain1, R Sharma1.   

Abstract

To explore the relationship between the structures of substituted pyrrolidine derivatives and their inhibition of dipeptidyl peptidase IV inhibitors. The QSAR, including CoMFA, CoMSIA and HQSAR, were applied to identify the key structures impacting their inhibitory potencies. The CoMFA, CoMSIA and HQSAR with cross-validated correlation coefficient (q2) value of 0.727, 0.870 and 0.939 and r2 value of 0.973, 0.981 and 0.949. Based on the structure-activity relationship revealed by the present study, we have designed a set of novel dipeptidyl peptidase IV inhibitors that showed excellent potencies in the developed models. Thus, our results allowed us to design new derivatives with desired activities.

Entities:  

Keywords:  CoMFA; CoMSIA; Dipeptidyl peptidase IV; Docking; HQSAR; Pyrrolidine

Year:  2017        PMID: 29098139      PMCID: PMC5653681          DOI: 10.1007/s40203-017-0032-2

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  24 in total

1.  3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA.

Authors:  Somayeh Pirhadi; Jahan B Ghasemi
Journal:  Eur J Med Chem       Date:  2010-08-10       Impact factor: 6.514

2.  QSAR models of cytochrome P450 enzyme 1A2 inhibitors using CoMFA, CoMSIA and HQSAR.

Authors:  J Sridhar; M Foroozesh; C L Klein Stevens
Journal:  SAR QSAR Environ Res       Date:  2011-10-17       Impact factor: 3.000

3.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

4.  Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential.

Authors: 
Journal:  Trends Endocrinol Metab       Date:  1999-08       Impact factor: 12.015

Review 5.  Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.

Authors:  Shrikanth H Havale; Manojit Pal
Journal:  Bioorg Med Chem       Date:  2009-01-31       Impact factor: 3.641

6.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA.

Authors:  Juan Zeng; Guixia Liu; Yun Tang; Hualiang Jiang
Journal:  J Mol Model       Date:  2007-07-06       Impact factor: 1.810

9.  3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents.

Authors:  U Saqib; M I Siddiqi
Journal:  SAR QSAR Environ Res       Date:  2009-07       Impact factor: 3.000

10.  Combined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as Aurora A kinase inhibitors.

Authors:  Yong Ai; Shao-Teng Wang; Ping-Hua Sun; Fa-Jun Song
Journal:  Int J Mol Sci       Date:  2011-03-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.